Status: Recruiting
A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)
This is a Randomized, Single-blind, Multi-center, Placebo-controlled, Phase 2a clinical trial of BX-001N to prevent patients from Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and subsequent Major Adverse Kidney Events (MAKE) in approximately 50 participants.
Participants needed: 50
Trial details
Phase: Phase 2Age: 19-90Biological sex: AllType: InterventionalSponsor: Bilix Co.,Ltd.Updated: Jul 1, 2026Locations: 8
Eligibility criteria
19 to 90 years of age [+8]
Participants scheduled for emergent or salvage cardiac surgery [+23]